A Trial of SHR-A2102 With Adebrelimab With or Without Other Antitumor Therapy in Advanced or Metastatic Non-small Cell Lung Cancer

PHASE1/PHASE2RecruitingINTERVENTIONAL

Enrollment

248

Participants

Timeline

Start Date

July 30, 2024

Primary Completion Date

October 31, 2026

Study Completion Date

October 31, 2026

Conditions

Advanced or Metastatic Non-small Cell Lung Cancer

Interventions

DRUG

SHR-A2102；Adebrelimab；Cisplatin/ Carboplatin

"Drug: SHR-A2102~Drug: Adebrelimab~Drug: Cisplatin/ Carboplatin"

Trial Locations (1)

RECRUITING

Chinese People's Liberation Army General Hospital, Beijing

All Listed Sponsors

lead

Shanghai Hengrui Pharmaceutical Co., Ltd.

INDUSTRY